Enzon Pharmaceuticals, INC Form 4 insider transactions

Carl C. Icahn and affiliated entities reported significant changes in beneficial ownership of Viskase Holdings, Inc. common stock following a merger and reverse stock split.

Enzon Pharmaceuticals, Inc. announced the successful completion of its exchange offer relating to Series C Non-Convertible Redeemable Preferred Stock.

Enzon Pharmaceuticals, Inc. announced a 1-for-100 reverse stock split and extended its Section 382 Rights Agreement, both in preparation for its merger with Viskase Companies, Inc.

Enzon Pharmaceuticals, Inc. announced an extension to its exchange offer for Series C Preferred Stock, now expiring on March 24, 2026, in connection with its proposed merger with Viskase Companies, Inc.

Enzon Pharmaceuticals, Inc. has announced the tenth amendment to its Section 382 Rights Agreement, extending the expiration date to March 24, 2026.

Enzon Pharmaceuticals, Inc. announced an extension of its exchange offer for Series C Preferred Stock until March 19, 2026, in connection with its proposed merger with Viskase Companies, Inc.

Enzon Pharmaceuticals, Inc. announced the eighth amendment to its Section 382 Rights Agreement and an extension of its Series C Preferred Stock exchange offer deadline.

Enzon Pharmaceuticals, Inc. announced that stockholders approved a 1-for-100 reverse stock split and the merger agreement with Viskase Companies, Inc.

Enzon Pharmaceuticals and Viskase Companies have amended their merger agreement, adjusting ownership ratios, reducing cash requirements, and extending the closing deadline to March 2026.

Enzon Pharmaceuticals, Inc. and Viskase Companies, Inc. have entered into a definitive merger agreement, with Viskase becoming a wholly owned subsidiary of Enzon, and the combined entity to be named Viskase Holdings, Inc. and trade on the OTCQX.